[From discovery to innovation: the example of hypereosinophilic syndrome].
Biomedical research is extremely productive so that each day new discoveries reveal novel (mechanisms and) molecular pathways of diseases. However, the number of innovative therapies approved each year by regulatory authorities is decreasing. The causes of this "innovation breakdown" are multiple and should be explored both in academic institutions and in the industrial world. New initiatives are underway in the Walloon Region to improve this situation, such as the setting up of the BioWin Health Cluster gathering pharmaceutical and biotechnology enterprises and university laboratories. This new vision of the partnership between academia and the private sector should be based on strong fundamental research activities. We illustrate this concept by discussing recent advances in the diagnosis and treatment of the hypereosinophilic syndrome.
Goldman
M
M
Institut d'Immunologie Médicale et Hôpital Erasme, Service de Médecine interne générale.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers / Q000032:analysis; D001709:Biotechnology; D054414:Chemokine CCL17; D019742:Chemokines, CC / Q000276:immunology; D015195:Drug Design; D004345:Drug Industry; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D007073:Immunoglobulin E / Q000096:biosynthesis; D018418:Th2 Cells / Q000276:immunology